Stoke Therapeutics (STOK) — closed signal from December 8, 2025
Partial Published before the outcome was known, scored automatically when the window closed on March 8, 2026.
Predicted vs. what happened
What happened
Reached 68% of the predicted growth at its peak, without hitting the target.
The thesis — published December 8, 2025
Stoke's stock jumped after very good results for its drug zorevunersen in a severe childhood epilepsy. The company and partner Biogen showed fewer seizures and some cognitive gains in long-term results. This makes investors more hopeful, but the program still faces trial, approval and funding hurdles, so the stock may swing a lot as people decide how to value the news.
Primary drivers
- Long-term results show fewer seizures and acceptable safety
- Working with Biogen gives the program extra credibility
- Still a clinical-stage drug, so approval and funding risks remain
- Strong investor enthusiasm can push price sharply up or down
How it played out
STOK: thesis partly played out but target was missed
Lyra published STOK at $31.27 on 2025-12-08 with expected growth of 40%. The thesis pointed to zorevunersen results in severe childhood epilepsy, fewer seizures, some cognitive gains, and Biogen's role. It also pointed to trial, approval, funding, and valuation risks.
Inside the window, STOK rose, but it did not reach the $43.78 target. The peak was $39.81 on 2026-03-02, with a 27.3% peak gain. It ended the window at $35.48 on 2026-03-08. The thesis partly played out. It never got there.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.